Bristol Myers Squibb obtained two US Food and Drug Administration approvals during the week of 7 April for combination therapy with its immuno-oncology stalwarts Opdivo (nivolumab) and Yervoy (ipilimumab) in liver and colorectal cancer settings, which should help the biopharma vie against strong competition in the IO space.
Key Takeaways
- Bristol’s Opdivo + Yervoy combo obtains FDA okays for colorectal and liver cancer settings.
- Each approval converted a prior accelerated approval for the combo in second-line treatment to a full approval in the first line
The new approvals brought the combination regimen’s list of indications to nine, according to BMS
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?